Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
about
Clinical impacts of a micropapillary pattern in lung adenocarcinoma: a reviewDifferences in driver genes between smoking-related and non-smoking-related lung cancer in the Chinese populationChina Experts Consensus on the Diagnosis and Treatment of Advanced Stage Primary Lung Cancer (2016 Version)The molecular background of mucinous carcinoma beyond MUC2Significance of persistent inflammation in respiratory disorders induced by nanoparticlesConcurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer.Establishment and characterization of a singaporean chinese lung adenocarcinoma cell line with four copies of the epidermal growth factor receptor gene.Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinomaRecent advances and clinical implications of the micropapillary histological subtype in lung adenocarcinomasImplementing the new IASLC/ATS/ERS classification of lung adenocarcinomas: results from international and Chinese cohorts.Comparison of clinical features, molecular alterations, and prognosis in morphological subgroups of lung invasive mucinous adenocarcinomaLung cancer molecular epidemiology in China: recent trendsEpidermal growth factor receptor gene mutation status and its association with clinical characteristics and tumor markers in non-small-cell lung cancer patients in Northwest ChinaMolecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER studyClinical significance of serum and urinary HER2/neu protein levels in primary non-muscle invasive bladder cancerClinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations.Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers.MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer.Prevalence of driver mutations in non-small-cell lung cancers in the People's Republic of China.HER2 mutations in Chinese patients with non-small cell lung cancer.Next-generation sequencing for lung cancer.Clinical impact of the new IASLC/ATS/ERS lung adenocarcinoma classification for chest surgeons.Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients.[China Experts Consensus on the Diagnosis and Treatment of Brain Metastases of Lung Cancer (2017 version)].Association between the CpG island methylator phenotype and its prognostic significance in primary pulmonary adenocarcinoma.ALK and ROS1 concurrent with EGFR mutation in patients with lung adenocarcinoma.Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer.Multidriver mutation analysis in pulmonary mucinous adenocarcinoma in Taiwan: identification of a rare CD74-NRG1 translocation case.Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: a prospective, single-institute study.Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients.ALK and ROS1 rearrangements, coexistence and treatment in epidermal growth factor receptor-wild type lung adenocarcinoma: a multicenter study of 732 cases.[Advances of the Role of Lung Cancer Driver Gene and PD-1/PD-L1 Pathway Interaction in the Tumorigenesis and Progression of Non-small Cell Lung Cancer].High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta™ Panel: exploring therapeutic targets.Epidermal growth factor receptor (EGFR) mutations as biomarker for head and neck squamous cell carcinomas (HNSCC).ALK fusion and its association with other driver gene mutations in Finnish non-small cell lung cancer patients.[Driver genes and its clinical significance in non-small cell lung cancer].[Advances of Pulmonary Adenocarcinoma with Micropapillary Pattern].Lung cancer in never smokers-the East Asian experience
P2860
Q26771950-BC343B05-9006-4576-876D-3C63538A1BC9Q26786594-563D0CD5-BD5F-4946-A652-FB9AC79C19BBQ28073920-F5CE7379-BD4B-41E1-84B4-1A23FB1ED064Q28083904-13DCA29D-4DFC-4F95-9AAD-353FFE059958Q28390890-38C933F4-6801-485C-8CB6-5D3F5E9D284EQ33648747-94A4B23D-6A61-4259-8108-42A8C83DC2AEQ33997316-D6D69300-397A-40F7-B3A6-D695949A13EDQ34073766-A39E7E37-3CCF-461E-BD76-DA119939D6E0Q34141249-27650DF0-4192-490F-BE95-F5D4E52FAAC4Q34404229-CB271009-9DFB-4C95-83AD-DCE9F2D448BFQ34567000-54283C36-08A6-4F5C-815E-85E8D4E41B4DQ35200702-53BD48E9-9063-48CD-A63E-CDB514C46BAFQ35802647-898BA130-EDF1-4B81-AB90-B9419DAC173BQ35849985-75B5E50F-4101-4358-B94C-D2BCDADADBC4Q36589225-31C02591-D72D-4EEF-8FB3-B73BD6AB705CQ37094986-A1D03890-E051-44C4-913A-EC85F762DA9FQ37269159-4D3E0E24-6CA3-4552-8077-9902DDAF530BQ37520331-B562DEBD-826E-4560-A9A3-5F910142BDA7Q37566819-75B2A350-1CF7-4AAD-BDF2-503CEBB6FD7FQ37718501-D4CA9B72-E902-4E37-AF91-A3B13736FA04Q38131798-0C1BE0FD-E952-41F2-AC8B-9A2854B67222Q38270567-FF517C40-AF15-4EE2-B68F-6391D8E7DA90Q39371891-93D2B3B2-A9C8-4AE8-9142-C706F14E5AE6Q40372968-9B6D60AC-BF35-4ECB-8EA6-7ABDDA97322CQ40915441-FBC6CA78-B029-42DB-BF0C-5C704520DAE0Q41037400-4C12C212-7EF6-45CC-871E-0FB0668A8081Q41302377-D0326C7B-CF0A-41D1-AF6D-DD3605C3B81DQ42213407-CD33183B-7B49-4208-9ABB-673CF95B8E22Q43542635-9DC4DF31-5892-441E-B476-B4F5DB96AAF6Q47127403-4966F31F-03B0-4243-A681-15CF4C6A6154Q47152298-E4B7775B-7D59-454E-B93A-F769F2BC3649Q49790309-C5D17B67-B8EB-4EF3-A7BC-3CBAF1793CCBQ53843394-617327C1-A361-4BE1-B456-C804467EF327Q54361563-80D8C731-B431-4B56-A557-754CFBB2994DQ55073653-42B47FAA-962A-4F11-9CC1-44D291A7CB0AQ55464378-CD92A85E-7C63-4D9F-8C32-7C39A10F589EQ55464905-81160E20-3FF5-4ADE-858B-AC7683D32C39Q58804388-4B252E00-052C-4871-939C-90655805A15F
P2860
Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Frequency of well-identified o ...... es and graduated smoking dose.
@en
Frequency of well-identified o ...... es and graduated smoking dose.
@nl
type
label
Frequency of well-identified o ...... es and graduated smoking dose.
@en
Frequency of well-identified o ...... es and graduated smoking dose.
@nl
prefLabel
Frequency of well-identified o ...... es and graduated smoking dose.
@en
Frequency of well-identified o ...... es and graduated smoking dose.
@nl
P2093
P1433
P1476
Frequency of well-identified o ...... es and graduated smoking dose.
@en
P2093
Chenguang Li
Haichuan Hu
Haiquan Chen
Yang Zhang
P356
10.1016/J.LUNGCAN.2012.09.018
P577
2012-10-23T00:00:00Z